53m
Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback